Company intelligence / Profile preview

VelosBio

San Diego, California, United Statesvelosbio.com ↗

Ownership: Private
Development stage: Other

Overview

In Phase 1 clinical trials, VLS-101 demonstrated a manageable safety profile and early signs of anti-tumor activity. Results showed objective clinical responses in 47% (7/15) of patients with mantle cell lymphoma and 80% (4/5) of patients with diffuse large B-cell lymphoma. Some patients achieved complete responses. These patients had been heavily pretreated with other anticancer medications before receiving VLS-101[2][8].

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)Bispecific antibodies
Industry: Biotech

Beyond the preview

Go deeper on VelosBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VelosBio.